Compare AMH & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMH | UTHR |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 20.3B |
| IPO Year | 2013 | 1999 |
| Metric | AMH | UTHR |
|---|---|---|
| Price | $30.83 | $489.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $38.20 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 2.5M | 424.3K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | ★ 23.05 | 16.08 |
| EPS | 1.18 | ★ 26.38 |
| Revenue | $1,831,836,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $8.29 | $13.64 |
| Revenue Next Year | $4.11 | $5.78 |
| P/E Ratio | $26.14 | ★ $18.55 |
| Revenue Growth | 7.71 | ★ 13.50 |
| 52 Week Low | $30.63 | $266.98 |
| 52 Week High | $39.49 | $492.62 |
| Indicator | AMH | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 68.10 |
| Support Level | $31.80 | $470.13 |
| Resistance Level | $32.73 | $492.62 |
| Average True Range (ATR) | 0.49 | 10.72 |
| MACD | -0.09 | -0.53 |
| Stochastic Oscillator | 9.31 | 89.55 |
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.